This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.08% per year. These returns cover a period from January 1, 1988 through May 6, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
UnitedHealth (UNH) Q4 Earnings Top Estimates, Revenues up Y/Y
by Zacks Equity Research
UnitedHealth's (UNH) fourth-quarter results benefit from higher revenues and return of healthcare utilization to normalcy level, partly offset by higher costs.
Demand for COVID-19 Tests to Drive Abbott (ABT) Q4 Earnings
by Zacks Equity Research
Within EPD, Abbott (ABT) is expected to have witnessed visible signs of rebound through Q4.
New Coronavirus Strain to Keep Telehealth Stocks in Demand
by Sapna Bagaria
Telemedicine is here to stay as the new coronavirus strain triggers a fear psychosis at large, thereby retaining solid demand for telehealth stocks.
Teladoc (TDOC) Stock Moves -0.13%: What You Should Know
by Zacks Equity Research
Teladoc (TDOC) closed at $225.25 in the latest trading session, marking a -0.13% move from the prior day.
3 Stocks to Watch Amid Expected Growth in Telehealth Sector
by Zacks Equity Research
The telehealth sector seems poised to maintain its robust growth in the future owing to the convenience it provides, making it a good time to keep an eye on names like Teladoc Health (TDOC) and Anthem (ANTM)
Digital Health M&As Gain Precedence in the New Normal
by Debanjana Dey
The booming digital health space has been witnessing significant M&A activities amid the pandemic.
5 Top-Performing ARK ETFs Worth Your Attention Now
by Sweta Jaiswal, FRM
Here we highlight some ETFs from the house of ARK Investment Management that have gained more than 100% in the past year for our investors to consider.
Cigna (CI) to Gain From Integrated Benefits & Lower Costs
by Zacks Equity Research
Cigna (CI) reinforces the importance of integrated benefits, which has been reducing healthcare costs and resulting in improved health conditions.
Teladoc (TDOC) and Dexcom Offer New Solutions for Diabetes
by Zacks Equity Research
Teladoc (TDOC) and Dexcom jointly provide solutions for patients with Type 2 diabetes, a common lifestyle-induced malady.
Cigna (CI) Extends MA Network With Iora for Better Healthcare
by Zacks Equity Research
Cigna's (CI) MA network expands with the inclusion of Iora Health. The move intends to provide improved health outcomes for seniors.
Teladoc (TDOC) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Teladoc (TDOC) closed at $204.15 in the latest trading session, marking a +1.58% move from the prior day.
The Zacks Analyst Blog Highlights: Zoom Video, Teladoc Health, PayPal, Tesla and First Solar
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Zoom Video, Teladoc Health, PayPal, Tesla and First Solar
5 Stocks to Benefit From the Top 5 Trends in 2021
by Radhika Pujara
Here we discuss the top five stocks, ZM, TDOC, PYPL, TSLA and FSLR, that are set to prosper on top five defining trends in 2021.
Teladoc (TDOC) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Teladoc (TDOC) closed at $199.96, marking a -1.77% move from the previous day.
Here's Why Hold Strategy is Apt For UnitedHealth Group (UNH)
by Zacks Equity Research
UnitedHealth Group (UNH) remains well-poised to benefit from growing revenues, robust Medicare business and a solid cash balance.
The Zacks Analyst Blog Highlights: Amazon, Apple, Walmart and Teladoc
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Amazon, Apple, Walmart and Teladoc
4 Stocks That Are Disrupting the Healthcare Sector
by Sapna Bagaria
The invasion of retailers and high-tech players in the healthcare are redefining age-old practices, thus bringing in changes that are here to last.
Is Competition Intensifying for Teladoc's (TDOC) Business?
by Zacks Equity Research
Teladoc (TDOC) might see heightening competition as Amazon fortifies its presence in telehealth space.
Teladoc Health (TDOC), WTI to Gain from Intel's Investment
by Zacks Equity Research
Teladoc Health (TDOC) continues to help WTI through the former's virtual platform, with the recent investment of Intel ramping up the work process of both the healthcare providers.
3 Telemedicine Stocks to Gain in 2021 on Digital Health Boom
by Debanjana Dey
Here are a few stocks which are gaining from the booming digital healthcare space and are likely to maintain momentum in 2021, making them prudent investment choices.
3 Telehealth Stocks to Keep Shaping the Future of Healthcare
by Sapna Bagaria
The need for touchless treatment, safety, ease, flexibility and efficiency in the current healthcare system makes telehealth a much sought-after option to provide care in the future.
The Zacks Analyst Blog Highlights: Quidel, Halozyme Therapeutics, Teladoc Health, Acceleron Pharma and BioCryst Pharmaceuticals
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Quidel, Halozyme Therapeutics, Teladoc Health, Acceleron Pharma and BioCryst Pharmaceuticals
5 Healthcare Stocks That Fared Well in 2020 Amid the Pandemic
by Zacks Equity Research
We take a sneak peek into five healthcare stocks that have performed well in 2020 driven by their improved capabilities to cope with the COVID-19 crisis.
Teladoc (TDOC) Up 130% YTD: Will the Rally Continue in 2021?
by Zacks Equity Research
Buoyancy in demand for telehealth consultation services along with a sturdy inorganic growth story will continue to push Teladoc's (TDOC) stock higher in 2021.
Buy Soaring Chewy Stock Before Q3 Earnings as E-Commerce Play?
by Benjamin Rains
Chewy (CHWY) is an e-commerce pet store that has expanded into telehealth and bolstered its pet medication offerings...